| Předmět: |
|
| Zdroj: |
Pharma Business Week; 2024, p416-416, 1p |
| Abstrakt: |
Cue Biopharma Inc. has been issued a patent for MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D). The patent describes the use of these polypeptides to modulate the activity of T cells and treat individuals with T1D. The invention involves the combination of T1D-associated peptide epitopes, MHC class II polypeptides, and immunomodulatory polypeptides. This patent provides potential new treatments for T1D and offers insights into the functioning of the immune system. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
